Shopping Cart 0
Cart Subtotal
USD 0

CMC Biologics AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

CMC Biologics A/S (CMC Biologics), formerly CMC Biopharmaceuticals A/S, a subsidiary of Asahi Glass Co., Ltd., is a contract process development and manufacturer of biopharmaceuticals. The company's service portfolio encompasses process development, cGMP manufacturing, and quality and regulatory services. Its process development services include cell culture development, upstream and downstream process development, analytical formulation stability for monoclonal antibodies. CMC Biologics' cGMP manufacturing services include mammalian cell culture and microbial fermentation. It also offers a proprietary Chinese hamster ovary cell line development platform called CHEF1, which delivers cell lines in rapid time frames. The company has manufacturing facilities in Berkeley, California and Seattle, Washington. CMC Biologics is headquartered in Copenhagen, Denmark.

CMC Biologics AS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CMC Biologics A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 10

Partnerships 11

CMC ICOS Biologics Enters into Co-development Agreement with Harpoon Therapeutics 11

Catalyst Biosciences Enters into Development and Manufacturing Services Agreement with CMC ICOS Biologics 12

CMC Biologics and IDT Biologika Enter into Agreement 13

CMC Biologics Enters into Agreement with Immunocore 14

CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 15

Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 16

CMC Biologics Enters into Co-Development Agreement with OncoSynergy for OS-2966 17

CMC Biologics Enters Into Agreement With OncoSynergy For OS2966 Drug Program 18

CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 19

Acquisition 20

Asahi Glass Acquires CMC Biologics for USD508.6 Million 20

CMC Biologics A/S-Key Competitors 22

CMC Biologics A/S-Key Employees 23

CMC Biologics A/S-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Strategy And Business Planning 25

Sep 20, 2018: AGC to Establish Mammalian cGMP-Compatible Contract Facility for Biopharmaceutical Development and Production at Chiba Plant 25

Corporate Communications 26

Jan 08, 2018: AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics 26

Appendix 27

Methodology 27

About GlobalData 27

Contact Us 27

Disclaimer 27


List Of Figure

List of Figures

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

CMC Biologics A/S, Pharmaceuticals & Healthcare, Key Facts 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CMC Biologics A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CMC Biologics A/S, Deals By Therapy Area, 2012 to YTD 2018 8

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 10

CMC ICOS Biologics Enters into Co-development Agreement with Harpoon Therapeutics 11

Catalyst Biosciences Enters into Development and Manufacturing Services Agreement with CMC ICOS Biologics 12

CMC Biologics and IDT Biologika Enter into Agreement 13

CMC Biologics Enters into Agreement with Immunocore 14

CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 15

Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 16

CMC Biologics Enters into Co-Development Agreement with OncoSynergy for OS-2966 17

CMC Biologics Enters Into Agreement With OncoSynergy For OS2966 Drug Program 18

CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 19

Asahi Glass Acquires CMC Biologics for USD508.6 Million 20

CMC Biologics A/S, Key Competitors 22

CMC Biologics A/S, Key Employees 23

CMC Biologics A/S, Other Locations 24

CMC Biologics A/S, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

CMC Biologics A/S (CMC Biologics), formerly CMC Biopharmaceuticals A/S, a subsidiary of Asahi Glass Co., Ltd., is a contract process development and manufacturer of biopharmaceuticals. The company's service portfolio encompasses process development, cGMP manufacturing, and quality and regulatory services. Its process development services include cell culture development, upstream and downstream process development, analytical formulation stability for monoclonal antibodies. CMC Biologics' cGMP manufacturing services include mammalian cell culture and microbial fermentation. It also offers a proprietary Chinese hamster ovary cell line development platform called CHEF1, which delivers cell lines in rapid time frames. The company has manufacturing facilities in Berkeley, California and Seattle, Washington. CMC Biologics is headquartered in Copenhagen, Denmark.

CMC Biologics AS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CMC Biologics A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 10

Partnerships 11

CMC ICOS Biologics Enters into Co-development Agreement with Harpoon Therapeutics 11

Catalyst Biosciences Enters into Development and Manufacturing Services Agreement with CMC ICOS Biologics 12

CMC Biologics and IDT Biologika Enter into Agreement 13

CMC Biologics Enters into Agreement with Immunocore 14

CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 15

Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 16

CMC Biologics Enters into Co-Development Agreement with OncoSynergy for OS-2966 17

CMC Biologics Enters Into Agreement With OncoSynergy For OS2966 Drug Program 18

CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 19

Acquisition 20

Asahi Glass Acquires CMC Biologics for USD508.6 Million 20

CMC Biologics A/S-Key Competitors 22

CMC Biologics A/S-Key Employees 23

CMC Biologics A/S-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Strategy And Business Planning 25

Sep 20, 2018: AGC to Establish Mammalian cGMP-Compatible Contract Facility for Biopharmaceutical Development and Production at Chiba Plant 25

Corporate Communications 26

Jan 08, 2018: AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics 26

Appendix 27

Methodology 27

About GlobalData 27

Contact Us 27

Disclaimer 27


List Of Figure

List of Figures

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

CMC Biologics A/S, Pharmaceuticals & Healthcare, Key Facts 2

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

CMC Biologics A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

CMC Biologics A/S, Deals By Therapy Area, 2012 to YTD 2018 8

CMC Biologics A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 10

CMC ICOS Biologics Enters into Co-development Agreement with Harpoon Therapeutics 11

Catalyst Biosciences Enters into Development and Manufacturing Services Agreement with CMC ICOS Biologics 12

CMC Biologics and IDT Biologika Enter into Agreement 13

CMC Biologics Enters into Agreement with Immunocore 14

CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 15

Serendex Pharma Enters into Agreement with CMC Biologics For Factor VII 16

CMC Biologics Enters into Co-Development Agreement with OncoSynergy for OS-2966 17

CMC Biologics Enters Into Agreement With OncoSynergy For OS2966 Drug Program 18

CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 19

Asahi Glass Acquires CMC Biologics for USD508.6 Million 20

CMC Biologics A/S, Key Competitors 22

CMC Biologics A/S, Key Employees 23

CMC Biologics A/S, Other Locations 24

CMC Biologics A/S, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS